Lisata Therapeutics(US:LSTA) Globenewswire·2025-11-06 13:00Core Insights - Lisata Therapeutics has been awarded "Overall BioPharma Solution of the Year" for its innovative therapies targeting advanced solid tumors, marking the second consecutive year of recognition [1][4][5] - The company utilizes its proprietary CendR Platform technology to enhance the delivery and efficacy of anti-cancer drugs, addressing unmet medical needs in oncology [2][6] Company Achievements - Over the past year, Lisata has reported significant clinical trial results, including a 60.8% six-month progression-free survival rate in the ASCEND Phase 2b trial for metastatic pancreatic ductal adenocarcinoma, compared to 25% for placebo [3] - The iLSTA trial for locally advanced, non-resectable pancreatic cancer achieved a 60% overall response rate and a 100% disease control rate, showcasing the effectiveness of its therapies [3][8] Technology and Innovation - The CendR Platform allows for more effective tumor-targeted delivery of anti-cancer drugs by activating the CendR transport mechanism, which enhances the penetration of drugs into solid tumors [2][6] - Certepetide, an investigational drug developed by Lisata, is designed to improve the uptake of anti-cancer therapies and has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers [7][8][9] Industry Context - The biotechnology sector is rapidly evolving, with innovations in gene therapies, precision medicine, and sustainable bio-manufacturing driving significant advancements in healthcare [4][5] - The BioTech Breakthrough Awards program highlights the importance of recognizing companies that contribute to transformative solutions in life sciences and biotechnology [5][10]